Article Sidebar

PDF
Date Published: 27/10/2023
Abstract Views: 114
Views PDF: 107
DOI: https://doi.org/10.51298/vmj.v531i1.6992
Issue
Vol. 531 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn , T. V. ., Nguyễn , T. V. ., Đỗ , A. T., & Vũ , H. T. . (2023). ASSESSMENT OF THE RESULTS OF STEP 1 TREATMENT OF STAGE IV NON-CELLULAR CANCER WITH EGFR MUTATIONS WITH OSIMETINIB. Vietnam Medical Journal, 531(1). https://doi.org/10.51298/vmj.v531i1.6992

ASSESSMENT OF THE RESULTS OF STEP 1 TREATMENT OF STAGE IV NON-CELLULAR CANCER WITH EGFR MUTATIONS WITH OSIMETINIB

Thị Vân Nguyễn 1, Thị Vân Nguyễn 1, Anh Tú Đỗ 1,, Hồng Thăng Vũ 2
1 k hospital
2 HMU

Main Article Content

Abstract

Objectives: Evaluation of results of first-line treatment of stage IV non-small cell lung cancer patients with EGFR mutations with osimtinib at K hospital from January 2018 to December 2022. Subjects and research methods: A retrospective and prospective cross-sectional descriptive study with longitudinal follow-up of 67 patients with stage IV non-small cell lung cancer with EGFR gene mutations, who received first-step treatment with osimtinib at K Hospital since January 1/2018 to December 2022. Result: The response rate was 82.1%, the disease control rate was 96.5%. The response rate at brain metastatic lesions was 88.6%. Median PFS was 17.6 months. PFS benefits were independent of age, sex, genetic mutation,  PS or brain metastases at the time of diagnosis (p>0.05). Conclusion: 1st step treatment using osimertinib in stage IV non-small cell lung cancer patients with EGFR mutations resulted in a high overall response rate as well as a brain response, prolonging progression-free survival.

Article Details

Keywords

Non-small cell lung cancer, EGFR, osimtinib, brain metastasis.

References

1. World Health Organization. Cancer - Key Facts. 2020.
2. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.
3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.
4. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. Cho BC,
5. Chewaskulyong B, Lee KH, et al. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. J Thorac Oncol. 2019;14(1):99-106.
6. Lorenzi M, Ferro A, Cecere F, et al. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2022;27(2):87-e115.
7. Pan-Chyr Yang Yuankai Shi, Joseph Siu-kie Au, et al. Molecular Epidemiological prospective study of EGFR mutation from Asian patients with advanced lung adenocarcinoma (PIONEER). J Clin Oncol. 2012; 30, 1534.
8. Mok T S, Wu YL, Ahn M J et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376(7), 629-640.